Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/181208
Autoantibody screening in Guillain–Barré syndrome
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.
Matèries (anglès)
Citació
Citació
LLEIXÀ, Cinta, MARTÍN AGUILAR, Lorena, PASCUAL GOÑI, Elba, FRANCO, Teresa, CABALLERO MILÁN, Marta, LUNA, Noemí de, GALLARDO, Eduard, SUÁREZ CALVET, Xavier, MARTÍNEZ MARTÍNEZ, Laura, DIAZ MANERA, Jordi, ROJAS GARCÍA, Ricard, CORTÉS VICENTE, Elena, TURÓN, Joana, CASASNOVAS PONS, Carlos, HOMEDES, Christian, GUTIÉRREZ GUTIÉRREZ, Gerardo, JIMENO MONTERO, María concepción, BERCIANO, José, SEDANO-TOUS, Maria josé, GARCÍA SOBRINO, Tania, PARDO FERNÁNDEZ, Julio, MÁRQUEZ INFANTE, Celedonio, ROJAS MARCOS, Iñigo, JERICÓ PASCUAL, Ivonne, MARTÍNEZ HERNÁNDEZ, Eugenia, MORÍS DE LA TASSA, Germán, DOMÍNGUEZ GONZÁLEZ, Cristina, JUÁREZ, Cándido, ILLA SENDRA, Isabel, QUEROL, Luis. Autoantibody screening in Guillain–Barré syndrome. _Journal of Neuroinflammation_. 2021. Vol. 18, núm. 1. [consulta: 20 de gener de 2026]. ISSN: 1742-2094. [Disponible a: https://hdl.handle.net/2445/181208]